These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21734220)

  • 21. Global stability analysis of humoral immunity virus dynamics model including latently infected cells.
    Elaiw AM
    J Biol Dyn; 2015; 9():215-28. PubMed ID: 26145479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamical analysis of a multi-strain model of HIV in the presence of anti-retroviral drugs.
    Sharomi O; Gumel AB
    J Biol Dyn; 2008 Jul; 2(3):323-45. PubMed ID: 22876872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Global stability for delay SIR and SEIR epidemic models with nonlinear incidence rate.
    Huang G; Takeuchi Y; Ma W; Wei D
    Bull Math Biol; 2010 Jul; 72(5):1192-207. PubMed ID: 20091354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of HIV models with two time delays.
    Alshorman A; Wang X; Joseph Meyer M; Rong L
    J Biol Dyn; 2017 Mar; 11(sup1):40-64. PubMed ID: 26889761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure.
    Vaz P; Chaix ML; Jani I; Macassa E; Bila D; Vubil A; Anderson S; Rouzioux C; Briand N; Blanche S
    Pediatr Infect Dis J; 2009 Dec; 28(12):e283-7. PubMed ID: 19907359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Asymptotic behavior of HIV-1 epidemic model with infinite distributed intracellular delays.
    Ali N; Zaman G
    Springerplus; 2016; 5():324. PubMed ID: 27066352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A mathematical model of cell-to-cell spread of HIV-1 that includes a time delay.
    Culshaw RV; Ruan S; Webb G
    J Math Biol; 2003 May; 46(5):425-44. PubMed ID: 12750834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
    Martinez-Picado J; Martínez MA
    Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persisting HIV-1 replication triggered by acute hepatitis A virus infection.
    Ridolfo AL; Rusconi S; Antinori S; Balotta C; Galli M
    Antivir Ther; 2000 Mar; 5(1):15-7. PubMed ID: 10846587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targets for inhibition of HIV replication: entry, enzyme action, release and maturation.
    Sierra-Aragón S; Walter H
    Intervirology; 2012; 55(2):84-97. PubMed ID: 22286875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensitivity analysis of a nonlinear lumped parameter model of HIV infection dynamics.
    Bortz DM; Nelson PW
    Bull Math Biol; 2004 Sep; 66(5):1009-26. PubMed ID: 15294416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic strategies towards HIV-1 infection in macrophages.
    Perno CF; Svicher V; Schols D; Pollicita M; Balzarini J; Aquaro S
    Antiviral Res; 2006 Sep; 71(2-3):293-300. PubMed ID: 16806514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Global stability of HIV infection of CD4+ T cells and macrophages with CTL immune response and distributed delays.
    Elaiw AM; Abukwaik RM; Alzahrani EO
    Comput Math Methods Med; 2013; 2013():653204. PubMed ID: 24363778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Global dynamics of a delayed within-host viral infection model with both virus-to-cell and cell-to-cell transmissions.
    Yang Y; Zou L; Ruan S
    Math Biosci; 2015 Dec; 270(Pt B):183-91. PubMed ID: 25998145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France.
    Chaix ML; Descamps D; Wirden M; Bocket L; Delaugerre C; Tamalet C; Schneider V; Izopet J; Masquelier B; Rouzioux C; Meyer L; Costagliola D; ; ;
    AIDS; 2009 Mar; 23(6):717-24. PubMed ID: 19279445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current approaches to treatment for HIV-1 infection.
    Powderly WG
    J Neurovirol; 2000 May; 6 Suppl 1():S8-S13. PubMed ID: 10871760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants.
    Van der Linden D; Hainaut M; Goetghebuer T; Haelterman E; Schmitz V; Maes P; Peltier A; Levy J
    Pediatr Infect Dis J; 2007 Apr; 26(4):359-61. PubMed ID: 17414406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Global properties of a delayed SIR epidemic model with multiple parallel infectious stages.
    Wang X; Liu S
    Math Biosci Eng; 2012 Jul; 9(3):685-95. PubMed ID: 22881032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A delayed HIV-1 model with cell-to-cell spread and virus waning.
    Li B; Jiao F
    J Biol Dyn; 2020 Dec; 14(1):802-825. PubMed ID: 33084532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.